Withdrawal: hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. [Withdrawals/Retractions]

This article has been withdrawn by the authors except for Hongzhe Li, who could not be reached. In Fig. 2C, lanes 7 and 14 of the p-ERK1/2 immunoblot are the same. In Fig. 2F, the upper p-ERK1/2 bands in lanes 3 and 4 are the same. Portions of the actin immunoblot from Fig. 2C are reused in Fig. 2, E and F. There are several duplicated features in the FACS plots shown in Fig. 3 (A and B). Portions of the Procaspase 3 immunoblot in Fig. 4B were reused in Procaspase 3 and BID immunoblots in Fig. 4D. The withdrawing authors do not agree with the Journal's analysis of Fig. 2G and Fig. 4 (C and E). The withdrawing authors state that magnification of the bands shows differences that exclude duplication. The withdrawing authors state that they repeated all of the relevant experiments and that the results are the same in their hands. The withdrawing authors state that the issues described above do not affect the interpretation of the data or conclusions of this work. This article characterizes the apoptosis-resistant function, in prostate cancer, of the novel molecule hPEBP4 identified by the authors from breast cancer. The withdrawing authors state that its function and mechanism have been confirmed in prostate cancer and other types of cancer by other independent studies (Li, W., et al. (2016) Biomed. Pharmacother. 81, 1–6; Huang, R., et al. (2019) Mol. Carcinog. 58, 135–143; Zhang, D., et al. (2016) Tumor Biol. 37,...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Withdrawals/Retractions Source Type: research